COYA
Coya Therapeutics, Inc.
There isn't enough reported data to score COYA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
COYA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
COYA's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
COYA PE Valuation
COYA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
COYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect COYA's revenue to grow, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
COYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.39 | -$0.28 |
| Q2 2026 | -$1.07 | +$0.17 |
| Q1 2026 | -$1.15 | -$0.08 |
| Q4 2025 | -$1.27 | -$0.29 |
| Q3 2025 | -$1.11 | -$0.45 |
| Q2 2025 | -$1.24 | -$0.50 |
| Q1 2025 | -$1.07 | -$0.21 |
| Q4 2024 | -$0.98 | -$0.19 |
COYA is still losing money, but less than at its worst: $1.39 per share over the past year, against $1.64 at its worst in early 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over COYA on earnings quality, reporting a profit while its opponent remains loss making.
COYA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $234.1K | -93% |
| Q2 2026 | $243.7K | +49% |
| Q1 2026 | $251.1K | -2.6% |
| Q4 2025 | $4M | +202769% |
| Q2 2025 | $163.6K | -95% |
| Q1 2025 | $257.9K | +103% |
COYA's revenue is growing: $234,134 last quarter, down 93% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4676% | -4608 points |
| Q2 2026 | -2891% | +1029 points |
| Q1 2026 | -3042% | -65 points |
| Q4 2025 | -152% | +208879 points |
| Q3 2025 | -68% | N/A |
| Q2 2025 | -3920% | -3826 points |
| Q1 2025 | -2977% | +1346 points |
| Q4 2024 | -209032% | N/A |
COYA's operating margin was −4676% last quarter, down 4608 points from the same quarter a year ago, near the bottom of its range since 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over COYA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over COYA on profitability, with a higher operating margin.
COYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -$6.1M |
| Q2 2026 | -$7.4M | -$1.6M |
| Q1 2026 | -$6.2M | -$3.4M |
| Q4 2025 | -$1M | +$1.4M |
| Q3 2025 | -$1.1M | +$4.3M |
| Q2 2025 | -$5.8M | -$1.2M |
| Q1 2025 | -$2.8M | -232% |
| Q4 2024 | -$2.4M | -$168.7K |
COYA has burned cash in almost every quarter: −$22M over the past year, against −$12M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over COYA on cash generation, producing positive trailing cash flow while its opponent burns cash.
COYA Net Leverage
COYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
COYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.9 | Neutral |
| Stochastic | 10.7 | Oversold |
COYA's weekly RSI is 37 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
COYA PE vs Healthcare Sector
COYA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
COYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.11 | 20% below |
| 20 week MA | $4.50 | 27% below |
| 50 week MA | $4.67 | 30% below |
| 100 week MA | $5.37 | 39% below |
| 200 week MA | $5.69 | 43% below |
COYA is in a downtrend: it's below all five of its weekly moving averages, and 43% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over COYA on trend strength, trading above more of its moving averages.
COYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $4.74 | $7.41 | +56% |
| 2024 | $7.41 | $5.92 | -20% |
| 2025 | $5.92 | $5.47 | -7.6% |
| 2026 YTD | $5.47 | $3.27 | -40% |
COYA has finished lower in two of the last three years. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over COYA on returns for 2026, with the stronger performance.